Centinel Spine Announces First Use of the Expanded prodisc C Family of Devices in US Clinical Study
Centinel Spine, LLC, the largest privately-held spine company focused on anterior column reconstruction, today announced that the first implantation took place in an Investigational Device Exemption (IDE) study monitored by the Food and Drug Administration (FDA). The two-level IDE clinical trial is a prospective, randomized, multi-centered clinical study evaluating two different cervical total disc replacement […]
- Posted on: Sep 3 2020